Productivity costs in patients with refractory chronic rhinosinusitis.
Productivity costs in patients with refractory chronic rhinosinusitis.
复制标题
DOI：
10.1002/lary.24630
复制
发表时间：
2014-09
期刊：
影响因子：
2.6
通讯作者：
Soler, Zachary M.
中科院分区：
文献类型：
--
作者：
Rudmik, Luke;Smith, Timothy L.;Schlosser, Rodney J.;Hwang, Peter H.;Mace, Jess C.;Soler, Zachary M.
患者生产力因疾病而降低可能会给社会带来巨大的经济损失。本研究的目的是：1) 定义难治性慢性鼻窦炎 (CRS) 患者的年度生产成本；2) 评估生产成本程度与 CRS 特定特征之间的关系。前瞻性、多机构、观察性队列研究。人力资本方法用于定义生产力成本。对年度缺勤、出勤和损失的休闲时间进行量化，以定义年度损失的生产时间 (LPT)。 LPT 使用从 2012 年美国全国人口普查和 2013 年美国劳工部统计数据获得的年日工资率进行货币化。共有 55 名难治性 CRS 患者入组。每年因缺勤和出勤而损失的平均工作日分别为 24.6 天和 38.8 天。与日常鼻窦护理需求相关，每年总共损失 21.2 个家庭日。每名难治性 CRS 患者的年度总体生产成本为 10,077.07 美元。生产力成本随着特定疾病生活质量的恶化而增加（r=0.440；p=0.001）。这项研究的结果表明，与难治性 CRS 相关的年生产力成本为每位患者 10,077.07 美元。这种巨大的社会成本强烈激励我们优化当前的治疗方案并继续评估新的临床干预措施以降低成本。
Disease-specific reductions in patient productivity can lead to substantial economic losses to society. The purpose of this study was to: 1) define the annual productivity cost for a patient with refractory chronic rhinosinusitis (CRS) and 2) evaluate the relationship between degree of productivity cost and CRS-specific characteristics. Prospective, multi-institutional, observational cohort study. The human capital approach was used to define productivity costs. Annual absenteeism, presenteeism, and lost leisure time was quantified to define annual lost productive time (LPT). LPT was monetized using the annual daily wage rates obtained from the 2012 US National Census and the 2013 US Department of Labor statistics. A total of 55 patients with refractory CRS were enrolled. The mean work days lost related to absenteeism and presenteeism was 24.6 and 38.8 days per year, respectively. A total of 21.2 household days were lost per year related to daily sinus care requirements. The overall annual productivity cost was $10,077.07 per patient with refractory CRS. Productivity costs increased with worsening disease-specific QoL (r=0.440; p=0.001). Results from this study have demonstrated that the annual productivity cost associated with refractory CRS is $10,077.07 per patient. This substantial cost to society provides a strong incentive to optimize current treatment protocols and continue evaluating novel clinical interventions to reduce this cost.
登录
查看更多内容
DOI：
10.1586/14737167.5.1.23
发表时间：
2005-02-01
影响因子：
2.3
作者：
Koopmanschap, Marc A
通讯作者：
Koopmanschap, Marc A
影响因子：
39.2
作者：
Pershing S;Enns EA;Matesic B;Owens DK;Goldhaber-Fiebert JD
通讯作者：
Goldhaber-Fiebert JD
影响因子：
3.3
作者：
Brouwer, WBF;Koopmanschap, MA;Rutten, FFH
通讯作者：
Rutten, FFH
影响因子：
5.4
作者：
Severens, JL;Mulder, J;Verbeek, ALM
通讯作者：
Verbeek, ALM
影响因子：
3.4
作者：
Bhattacharyya, Neil;Orlandi, Richard R.;Martinson, Melissa
通讯作者：
Martinson, Melissa